Application of Full-Spectrum Rapid Clinical Genome Sequencing Improves Diagnostic Rate and Clinical Outcomes in Critically Ill Infants in the China Neonatal Genomes Project
- PMID: 33935161
- DOI: 10.1097/CCM.0000000000005052
Application of Full-Spectrum Rapid Clinical Genome Sequencing Improves Diagnostic Rate and Clinical Outcomes in Critically Ill Infants in the China Neonatal Genomes Project
Abstract
Objectives: To determine the diagnostic and clinical utility of trio-rapid genome sequencing in critically ill infants.
Design: In this prospective study, samples from critically ill infants were analyzed using both proband-only clinical exome sequencing and trio-rapid genome sequencing (proband and biological parents). The study occurred between April 2019 and December 2019.
Setting: Thirteen member hospitals of the China Neonatal Genomes Project spanning 10 provinces were involved.
Participants: Critically ill infants (n = 202), from birth up until 13 months of life were enrolled based on eligibility criteria (e.g., CNS anomaly, complex congenital heart disease, evidence of metabolic disease, recurrent severe infection, suspected immune deficiency, and multiple malformations).
Interventions: None.
Measurements and main results: Of the 202 participants, neuromuscular (45%), respiratory (22%), and immunologic/infectious (18%) were the most commonly observed phenotypes. The diagnostic yield of trio-rapid genome sequencing was higher than that of proband-only clinical exome sequencing (36.6% [95% CI, 30.1-43.7%] vs 20.3% [95% CI, 15.1-26.6%], respectively; p = 0.0004), and the average turnaround time for trio-rapid genome sequencing (median: 7 d) was faster than that of proband-only clinical exome sequencing (median: 20 d) (p < 2.2 × 10-16). The metagenomic analysis identified pathogenic or likely pathogenic microbes in six infants with symptoms of sepsis, and these results guided the antibiotic treatment strategy. Sixteen infants (21.6%) experienced a change in clinical management following trio-rapid genome sequencing diagnosis, and 24 infants (32.4%) were referred to a new subspecialist.
Conclusions: Trio-rapid genome sequencing provided higher diagnostic yield in a shorter period of time in this cohort of critically ill infants compared with proband-only clinical exome sequencing. Precise and fast molecular diagnosis can alter medical management and positively impact patient outcomes.
Copyright © 2021 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
Conflict of interest statement
The authors have disclosed that they do not have any potential conflicts of interest.
Comment in
-
Whole Genome Sequencing as a First-Line Clinical Test: Almost Ready for Prime Time.Crit Care Med. 2021 Oct 1;49(10):1815-1817. doi: 10.1097/CCM.0000000000005077. Crit Care Med. 2021. PMID: 34529612 No abstract available.
References
-
- Wojcik MH, Schwartz TS, Yamin I, et al.: Genetic disorders and mortality in infancy and early childhood: Delayed diagnoses and missed opportunities. Genet Med. 2018; 20:1396–1404
-
- Smith LD, Willig LK, Kingsmore SF: Whole-exome sequencing and whole-genome sequencing in critically ill neonates suspected to have single-gene disorders. Cold Spring Harb Perspect Med. 2015; 6:a023168
-
- Willig LK, Petrikin JE, Smith LD, et al.: Whole-genome sequencing for identification of Mendelian disorders in critically ill infants: A retrospective analysis of diagnostic and clinical findings. Lancet Respir Med. 2015; 3:377–387
-
- Lionel AC, Costain G, Monfared N, et al.: Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test. Genet Med. 2018; 20:435–443
-
- Wang H, Lu Y, Dong X, et al.: Optimized trio genome sequencing (OTGS) as a first-tier genetic test in critically ill infants: Practice in China. Hum Genet. 2020; 139:473–482
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
